Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 21;8(12):1306–1317. doi: 10.1002/sctm.19-0145

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Differentiation capacity of hMSC from osteoporotic patients. (A, B): Quantitative PCRs showing the relative expression levels of different osteogenic markers (Runx2 and Alpl) in hMSCs from osteoporotic patients (MSC‐OP) transfected with a control GapmeR and a GapmeR for the silencing of Smurf1. Graphs show expression of the analyzed markers in the presence of different doses of BMP‐2. Values reflect averages of triplicate samples. (B) Graph showing a significant increase in the Alpl activity in MSC‐OP treated with the Smurf1 GapmeR and differentiated for 8 days in the presence of 10 ng/ml BMP‐2. (C): Osteogenic differentiation of the same hMSCs‐OP transfected with the Smurf1 GapmeR and differentiated in the presence of 10 ng/ml BMP‐2 as revealed by Alizarin red staining bars represent standard error of the mean values. p‐Values are indicated.